Depression: all studies (page 31) - The Consciousness Library

The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.

Journal of Psychiatric Research June 1, 2026 Kyle Valentino, Hana Ballum, William Cheung et al.

Approximately 80% of individuals diagnosed with major depressive disorder (MDD) report symptoms of insomnia. Glutamatergic modulators, such as ketamine, are reported to be effective for the treatment of depressive symptomatology in adults with MDD. Disrupted glutamate homeostasis is linked to poor sleep quality and sleep disorders. Herein, we sought to systematically determine the effect of...

DOI: 10.1016/j.jpsychires.2026.02.011 Full text Depression Early morning awakening Gamma-aminobutyric acid gaba Glutamate +2

Trait mindfulness influences self-reported mental health in individuals with depression

Current Psychology June 1, 2026 Geovan Menezes de Sousa, Geissy Lainny de Lima-Araújo, Vagner Deuel de Oliveira Tavares et al.

Abstract Dispositional mindfulness, also known as trait mindfulness, refers to an individual dispositional tendency to attend the present moment experiences with openness, curiosity and awareness. It is often associated with well-being, particularly through its role with emotional regulation. Yet, it is not well understood how it may influence the expression of major depression symptoms. This...

DOI: 10.1007/s12144-026-09635-z Full text Mindfulness Major depressive disorder Mental health Depression economics +7

Psilocybin shows rapid relief for depression symptoms

Mental Health Weekly June 1, 2026 Valerie A. Canady

A single dose of psilocybin may provide rapid relief for people with major depressive disorder (MDD), with benefits emerging within days and lasting for several weeks, according to a randomized clinical trial published May 15 in JAMA Network Open . Researchers of the study, “Short‐Term and Late‐Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial,” found that...

DOI: 10.1002/mhw.34890

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

European Neuropsychopharmacology June 1, 2026 Andreas Reif, Yağcıoğlu Ae Anıl, Istvan Bitter et al. 3 citations

Optimising patient outcomes in treatment resistant depression (TRD) requires treatments which provide sustained remission, without relapse, and tolerability in the long term. ESCAPE-LTE (NCT04829318) was a phase IV, single-arm, 2-year (104 weeks) long-term extension of ESCAPE-TRD (NCT04338321; 32 weeks), a rater-blinded, randomised, active-controlled trial, which evaluated the safety,...

DOI: 10.1016/j.euroneuro.2026.112801 Full text Esketamine nasal spray Major depressive disorder Efficacy Long-term +3

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study.

Journal of Psychiatric Research June 1, 2026 Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.

In patients with treatment-resistant depression (TRD), the efficacy and tolerance of intranasal esketamine (ESK) spray, alone or combined with oral antidepressants, has been supported by clinical trials and observational studies. The French real-world ESKALE study assessed the benefit of ESK in 157 patients with TRD. In this post-hoc analysis of the ESKALE study we aimed to describe the...

DOI: 10.1016/j.jpsychires.2026.03.011 Full text Esketamine Treatment-resistant depression Dissociation Efficacy +1

Regional Blood Flow Signatures of Opioidergic Modulation of Ketamine in Major Depressive Disorder: A Randomized Crossover Study.

American Journal of Psychiatry June 1, 2026 Luke A. Jelen, Owen O'Daly, Fernando O Zelaya et al. 2 citations

Accumulating evidence suggests that the opioid system may modulate ketamine's rapid antidepressant effects. The objective of this study was to test whether opioid system modulation via naltrexone alters ketamine's acute effects on regional cerebral blood flow (rCBF) in major depressive disorder (MDD), and whether these changes relate to symptom measures and map onto receptor density profiles....

DOI: 10.1176/appi.ajp.20250903 Full text Depressive disorders Ketamine/esketamine Neuroimaging Psychopharmacology

Effectiveness of IV Ketamine Therapy in the Management of Treatment Resistant Depression

BJPsych Open June 1, 2026 Imtiaz Ahmad Dogar, Palvisha Sajid, Dua Fatima et al.

Aims: In the light of limited relevant local literature, we planned our research to build a scientific database related to the immediate and sustained effects of this innovative treatment modality at our tertiary care hospital, in order to start ketamine clinic in our department . We didn’t find any research in Faisalabad, Pakistan on the subject, ensuring a more in depth understanding of the...

DOI: 10.1192/bjo.2026.11855 Full text Treatment-resistant depression Tolerability Informed consent Adverse effect +11

Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm.

Asian Journal of Psychiatry June 1, 2026 Fabiola Raffone, Filippo Mazzoni, Arianna De Ciechi et al. 3 citations

Suicidal ideation and deliberate self-harm are frequent and persistent in treatment-resistant depression (TRD), particularly when comorbid borderline personality disorder (BPD) is present. Real-world evidence on antisuicidal outcomes during intranasal esketamine in this population remains limited. In this multicentre prospective observational study, 90 outpatients with TRD received intranasal...

DOI: 10.1016/j.ajp.2026.104983 Full text Esketamine Treatment-resistant depression Borderline personality disorder Self-harm +2

Ketamine infusion combined with accelerated sequential theta burst stimulation in multi-therapy-resistant bipolar depression: A case report.

Asian Journal of Psychiatry June 1, 2026 Hariprasad Ganapathy Vijayakumar, Varsha Shamanna, Harsh Pathak et al. 1 citation

Treatment resistance in bipolar depression is one of the most challenging clinical conditions to treat in psychiatry. We present a case of an elderly gentleman with chronic Multi-Therapy Resistant Bipolar Depression (MTRBD), where ketamine, a preferential NMDAR blocker on cortical GABAergic interneurons, is used adjunctively with sequential theta burst stimulation (sTBS) to achieve remission....

DOI: 10.1016/j.ajp.2026.104994 Full text Neuroplasticity Brain stimulation Depressive episode Neuromodulation +1

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

American Journal of Psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations

Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...

DOI: 10.1176/appi.ajp.20250840 Full text Major depressive disorder Bipolar disorder Buprenorphine Ketamine/esketamine +1